5 biggest risks of sharing your DNA with consumer genetic-testing companies
By Eric Rosenbaum,
CNBC [Cites CGS' Marcy Darnovsky]
| 06. 16. 2018
The business of personal genetic-testing kits is booming, with consumers able to learn about their ancestry and health risks at the cost of just $99 to a few hundred dollars. Should you be afraid?
Some individuals worry they will discover things about their DNA that will be frightening — namely, the risks they run of contracting various diseases — and not know how to move forward with the information. Professional scientific skeptics contend the information may not even be as accurate as claimed, and lead people to make questionable health decisions. But there's another type of risk that consumers aren't focusing on as much, and it's a big one: privacy. There is nothing more private than your personal genetic information, and sending away for a personal genome kit means sharing your DNA with the testing companies. What do they do with it, beyond providing consumers with genetic and health assessments?
More than 80 percent of 23andMe customers agree to let the company share their DNA with research partners.
That's a question consumers need to weigh as they consider genome testing...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...